Ampligen Chronic Fatigue Syndrome Data May Be Sufficient For FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is reviewing Hemispherx’s reanalysis of data from its Ampligen Phase III trial to determine if an additional confirmatory study is necessary.
You may also be interested in...
FDASIA Expedited Approval Provisions Offer Little Help To Ampligen
Despite Hemispherx’s initial belief that the chronic fatigue syndrome drug might qualify under the FDA Safety and Innovation Act’s language encouraging increased use of accelerated approval, FDA officials suggest the pathway is not an option and the drug’s effect on an intermediate clinical endpoint has not been adequately demonstrated.
FDA Uses AdComm Process To Shine Light On Ampligen’s Troubled Development
December’s Arthritis Advisory Committee review of Hemispherx’s drug provided FDA with the first public opportunity to explain in detail why the chronic fatigue syndrome drug, in development for almost 25 years, has not passed regulatory muster to date.
FDA Takes Dim View Of Ampligen For Chronic Fatigue Syndrome
In review documents released ahead of a Dec. 20 advisory committee meeting, agency questions the validity of Hemispherx’s post-hoc efficacy analyses and raises concerns about adverse events and the reliability of the safety data.